1827. Impact of an antibiotic stewardship program in long-term care facilities: A nursing home network experience
Session: Oral Abstract Session: Thinking Beyond Your Hospital: Stewardship on a Broader Scale
Saturday, October 7, 2017: 11:30 AM
Room: 01AB

Background: Antibiotic stewardship program (ASP) implementation is paramount across the healthcare spectrum. Nursing homes represent a challenge due to limited resources, complexity of medical conditions, and less controlled environments.  National statistics on ASP for long-term care facilities (LTCF) are sparse.

Methods: A pilot ASP was launched in August 2016 at a 270-bed nursing home with a 50-bed chronic ventilator-dependent unit. The program entailed a bundle of interventions including leadership engagement, a tracking and reporting system for intravenous antibiotics, education for caregivers, Infectious Disease (ID) consultant availability, and implementation of nursing protocols. Data were collected from pharmacy and medical records between Jan/16 and Mar/17, establishing pre-intervention and post-intervention periods. Collected data included days of therapy (DOT), antibiotic costs, resident-days, hospital transfers, and Clostridium difficile infection (CDI) rates. Variables were adjusted to 1000 resident-days (RD) and findings between periods were compared by Mann-Whitney U test. 

Results: A total of 47,423 resident-days and 1,959 DOT were analyzed for this study. Antibiotic use decreased from 54.5 DOT/1000 RD pre-intervention to 27.6 DOT/1000 RD post-intervention (p= 0.017). Antibiotic costs were reduced from a monthly median of US $17,113 to US $7,073 but was not statistically significant (p=0.39). Analysis stratified by individual antibiotic was done for the five most commonly used antibiotics and found statistically significant reduction in vancomycin use (14.4 vs 6.5; p=0.023). Reduction was also found for cefepime/ceftazidime (6.9 vs 1.3; p= 0.07), ertapenem (6.8 vs 3.6; p= 0.45), and piperacillin/tazobactam (1.8 vs 0.6; p=0.38). Meropenem use increased (1.3 vs 3.2; p=0.042).  Hospital transfers slightly trended up (6.73 vs 7.77; p=0.065), and there was no change in CDI (1.1 s 0.94; p=0.32).  

Conclusion:  A bundle of standardized interventions tailored for LTCF can achieve successful reduction of antibiotic utilization and costs. Subsequent studies are needed to further determine the impact on clinical outcomes such as transfers to hospitals and CDI in these settings.

Fabian Andres Romero, MD, Infectious Disease, NMS Healthcare, Hyattsville, MD, Evette Mathews, RN, MSN, MBA, Clinical services, NMS Healthcare, Hyattsville, MD, Ara Flores, BSN, RN, Infection Control, NMS Healthcare, Hyattsville, MD and Susan Seo, MD, Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Disclosures:

F. A. Romero, None

E. Mathews, None

A. Flores, None

S. Seo, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.